ETF Evaluator:
Tema Oncology ETF ()
Follow This ETF
(as of Aug 26)
Best Performing in Health Over the Last Year
| 129.4% | Virtus LifeSci Biotech Clinical Trls ETF (BBC) |
| 94.1% | ALPS Medical Breakthroughs ETF (SBIO) |
| 88.4% | F/m Emerald Life Sciences Innovation ETF (LFSC) |
| 72.5% | State Street® SPDR® S&P® Biotech ETF (XBI) |
| 65.8% | State Street® SPDR® S&P® PhrmctlsETF (XPH) |
Risk
Index
Risk
Index
ETF Details
Tema Oncology ETF Overview
Tema Oncology ETF (CANC) is an actively managed Sector Equity Health exchange-traded fund (ETF). Tema ETFs launched the ETF in 2023.
The investment seeks to provide long-term growth.
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
About Tema Oncology ETF (CANC)
There are 5 members of the management team with an average tenure of 1.95 years: Yuri Khodjamirian (2023), Andrew Hicks (2026), Qiao Duan (2026), Maurits Pot (2023) and David Song (2023). Management tenure is more important for actively managed ETFs than passive index ETFs.
The ETF has 1 primary benchmark: S&P 500 (TR) index with a weighting of 100%. Tema Oncology ETF has 59 securities in its portfolio. The top 10 holdings constitute 42.6% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is not considered to have an ESG focus with its investment selection and management.
Tema Oncology ETF is part of the Equity global asset class and is within the Sector Equity ETF group. Tema Oncology ETF has 16.1% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is 82.6% There is 16.1% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Tema Oncology ETF has 1.3% of the portfolio in cash.
Assets Under Management
The fund has $193 million in total assets, which is below the $1 billion average for the Health category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
CANC Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Tema Oncology ETF expense ratio is above average compared to funds in the Health category. Tema Oncology ETF has an expense ratio of 0.75%, which is 45% higher than its category average, making the fund expense ratio grade a F. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Tema Oncology ETF has a portfolio turnover rate of 68%, which indicates that it holds its assets around / 0.0 years. By way of comparison, the average portfolio turnover is 45% for the Health category.
Recently, in the month of July 2026, Tema Oncology ETF returned -1.3%, which earned it a grade of D, as the Health category had an average return of -0.1%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
Tema Oncology ETF has a trailing yield of 0.05%, which is below the 1.10% category average.
The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
Tema Oncology ETF Grades
Year to date, the ETF has returned 17.0%, 7.3 percentage points better than the category, which translates into a grade of B. The fund has returned 56.8% over the past year (grade of A).
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Tema Oncology ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
CANC Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| CANC Return (NAV) | -1.3% | 8.1% | 56.8% | na | na | na |
| CANC Return (Price) | -1.6% | 8.2% | 56.8% | na | na | na |
| NAV +/- Price Return | 0.302% | -0.084% | -0.075% | na | na | na |
| Health Avg | -0.1% | 11.2% | 36.9% | 9.9% | 1.6% | 8.7% |
| CANC Grade (NAV) | D | F | A | na | na | na |
| +/- Category (NAV) | -1.2% | -3.1% | 19.9% | na | na | na |
| CANC Tax-Cost Ratio | na | na | 0.0% | na | na | na |
CANC Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| CANC Return (NAV) | 17.0% | 42.8% | -4.5% | na | na | na | na | na | na | na | na |
| CANC Return (Price) | 16.9% | 42.9% | -4.5% | na | na | na | na | na | na | na | na |
| NAV +/- Price Ret | -0.005% | 0.003% | 0.006% | na | na | na | na | na | na | na | na |
| Health Avg | 9.7% | 21.8% | 0.1% | 2.2% | -16.3% | 4.3% | 30.5% | 25.4% | -1.5% | 26.5% | -10.2% |
| CANC Grade (NAV) | B | A | F | na | na | na | na | na | na | na | na |
| +/- Category | 7.3% | 21.0% | -4.6% | na | na | na | na | na | na | na | na |
| Risk Measures | |
| Beta: | na |
| R-Squared: | na |
| Standard Deviation: | na |
| Category Risk Index: | na |
| Category Risk Rating: | |
| Total Risk Index: | na |
| Total Risk Rating: | |
| Portfolio Characteristics | |
| Yield: | 0.1% |
| Total Assets: | $ 193 Mil |
| Share Class Assets: | $ 193 Mil |
| Turnover: | 68.0% |
| Expense Ratio: | 0.75% |
| Index Fund: | No |
| Index Tracked: | S&P 500 (TR) |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | No |
| Capital Gains Distribution Frequency: | Annually |
| Income Distribution Frequency: | Annually |
Management Team
| Number of Managers: 5 | |||
| Longest Tenure: 3.0 years | |||
| Average Tenure: 2.0 years | |||
| Managers (Year): Khodjamirian Yuri (2023), Pot Maurits (2023), Song David (2023), Hicks Andrew (2026), Duan Qiao (2026) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 59 |
| % in Top 10 Holdings: | 42.6% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 16.1% |
Portfolio Allocation |
|
| Domestic Stock: | 82.6% |
| Foreign Stock: | 16.1% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 1.3% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | Tema ETFs |
| Phone Number: | 888-744-1377 |
| Website: | www.tema.co |
| Inception Date: | August 14, 2023 |
Expenses and Fees
| Expense Ratio (%): | 0.75% (Rating: Above Avg) |
| Category Average Expense Ratio (%): | 0.52% |
